Skip to main content
Hubei Biocause Heilen Pharmaceutical Co., Ltd. logo

Hubei Biocause Heilen Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301211 ISIN · CNE100005782 LEI · 6556002YCBVIKGZODE80 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 421 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301211

About Hubei Biocause Heilen Pharmaceutical Co., Ltd.

https://www.biocause.com

Hubei Biocause Heilen Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company is recognized as a leading global producer of Ibuprofen, maintaining large-scale production facilities that adhere to international quality standards including GMP, FDA, and EDQM certifications. Its product portfolio encompasses a wide range of chemical synthetic drugs, pharmaceutical intermediates, and preparations across various therapeutic categories. The company focuses on technological innovation and rigorous quality control to serve a diverse global clientele. By leveraging advanced chemical synthesis technologies and integrated production chains, it provides high-purity pharmaceutical components to healthcare providers and pharmaceutical manufacturers worldwide.

Recent filings

Filing Released Lang Actions
关于公司通过巴西国家卫生监督局GMP认证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of GMP certification from the Brazilian National Health Surveillance Agency (ANVISA). It includes details about the certification, its scope, validity, and the impact on the company. The document is short (687 characters) and serves as an official announcement of a regulatory approval rather than a financial report or detailed operational report. There is no financial data, no mention of annual or quarterly results, no management discussion, no voting results, or other report types. It is a regulatory announcement about certification compliance, which fits best under Regulatory Filings (RNS).
2026-05-07 Chinese
第二届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 18th meeting of the 2nd Board of Directors of Hubei Hendy Pharmaceutical Co., Ltd. It includes approval of the 2025 Annual Report, 2025 Annual Financial Statements, profit distribution plan, internal control self-assessment report, and other governance-related reports. The document also mentions that these reports are published separately on the official disclosure platform (cninfo.com.cn) and will be submitted to the 2025 Annual General Meeting for approval. The document itself is a formal board meeting resolution announcement rather than the full annual report or financial statements. It is under 5,000 characters and primarily serves to announce the board's decisions and the upcoming shareholder meeting. Therefore, it fits best into the category of Board/Management Information (MANG), as it announces board meeting resolutions and management decisions rather than containing the full reports themselves.
2026-03-30 Chinese
2025年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2025年度财务决算报告 (2025 Annual Financial Settlement Report) of 湖北亨迪药业股份有限公司, containing detailed financial statements including balance sheet, income statement, cash flow statement, and notes. It mentions an audit report by 大信会计师事务所 with an unqualified opinion, indicating it is a full audited annual financial report. The document includes comprehensive financial data for the full fiscal year 2025, with comparisons to 2024, detailed explanations of major financial items, and cash flow analysis. The length is 3735 characters, which is sufficient for a detailed report rather than a brief announcement. The content matches the characteristics of an Annual Report (10-K) rather than a short announcement or certification. Therefore, the document should be classified as an Annual Report (10-K). FY 2025
2026-03-30 Chinese
2025年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Storage and Actual Use of Raised Funds for the Year 2025." It details the company's fundraising activities, the amount of funds raised, their storage, usage, changes in investment projects, and compliance with regulatory requirements. It references regulatory rules from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed tables on the use of raised funds, project progress, and changes in fund usage. The document is about the management and use of capital raised through share issuance, not a general financial report or earnings release. It is a specialized report focused on capital raising and fund usage compliance. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes. The document length is sufficient and contains substantive data on fundraising and fund usage, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2026-03-30 Chinese
2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (auditor) for the 2025 annual audit of 湖北亨迪药业股份有限公司. It details the auditor's qualifications, audit process, quality control, and compliance with regulations. It does not contain the actual audited financial statements or the full annual report but rather assesses the auditor's performance and adherence to standards during the audit engagement. The document length is 3279 characters, which is relatively short and focused on audit quality evaluation rather than financial results. This matches the description of an Audit Report / Information (AR) which includes standalone audit reports and audit-related evaluations, excluding full annual reports. Therefore, the correct classification is AR with high confidence. FY 2025
2026-03-30 Chinese
2025年年度审计报告
Audit Report / Information Classification · 98% confidence The document is a standalone audit report issued by a certified public accounting firm (大信会计师事务所) containing an audit opinion, basis of opinion, key audit matters, auditor responsibilities, and the audited consolidated and parent company financial statements for the year ended December 31, 2025. It does not include broader narrative, MD&A, or supplementary investor presentation material and is clearly labeled “审计报告,” fitting the definition of an Audit Report/Information. FY 2025
2026-03-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.